Key clinical point: Analysis led to development of a simple yet clinically robust bundled payment model for head and neck cancer based solely on treatment types.
Major finding: Treatment cost was the main driver in the analysis, leading to a three-tiered model in which single-modality treatment was least costly, followed by bimodality therapy and trimodality therapy.
Study details: An analysis of factors driving cost among 150 patients with stage 0 to IVA head and neck cancer.
Disclosures: Study coauthors provided disclosures related to AstraZeneca, Blue Earth Diagnostics, Merck, Varian Medical Systems, UpToDate, Gerson Lehrman Group, Osler, AlignRT, Chrysalis Biotherapeutics, and others.
Tom MC et al. J Oncol Pract. 2019 Apr 22. doi: 10.1200/JOP.18.00665.
This Week's Must Reads
Must Reads in Head & Neck Cancers
Monalizumab + cetuximab is active in advanced SCC of the head and neck, Cohen R et al. SITC 2018, Abstract 051
Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR
Head and neck cancer therapy toxicities greater in women, Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.